Revolutionary treatment for psoriasis

Three per cent of the world's population suffer from the skin condition known as psoriasis. A Norwegian research-based company is close to developing a treatment that could help millions. The research may also prove beneficial in the treatment of other illnesses.

The psoriasis treatment consists of a compound which, when applied to the skin, is absorbed by much more naturally than most other ointments. It contains a synthesised molecule based on the fatty acid docosahexaenoic acid () which may prove effective in inhibiting associated with psoriasis.

Clinical trials soon underway

Avexxin, a Trondheim-based company, is to begin clinical testing of the ointment in early 2013. If the results are positive, Avexxin may find itself on the cusp of an international breakthrough.

Successful tests of the psoriasis compound could also give an important boost to the pursuit of more comprehensive clinical trials to determine whether the technology can be applied to other such as rheumatoid arthritis and nephritis, an inflammation in the kidneys.

Combining clinical phases 1 and 2A

Clinical trials often extend over a long period of time. The treatment must first be tested for toxicity on healthy volunteers. Subsequent trials must be carried out on real patients to ensure that the treatment has the desired effect. With an ointment such as this, which is to be applied externally, it is possible to combine trial phases 1 and 2A.

"This enables us to save a lot of time," explains Professor Berit Johansen of the Norwegian University of Science and Technology (NTNU). Dr Johansen has been studying the mechanisms behind inflammatory disease since the end of the 1980s. She launched the company, Avexxin, in 2005.

Potential for treating other conditions

Two Avexxin projects have received funding under the programme for User-driven Research-based Innovation (BIA) at the Research Council of Norway:

  • Development of mechanism based, novel anti-inflammatory compounds (2006-2009)
  • Expanding drug pipeline in Avexxin - adopting new chemistry (2009-2012)
"We have been lucky in obtaining private funding that supports our main focus – the development of a medicine for treating psoriasis," Dr Johansen explains.

"The financial support we have received from the Research Council has been critical to our research and has enabled us to develop several molecules to treat other inflammatory conditions with the same target as psoriasis. These molecules could prove effective in treating and nephritis," Dr Johansen states.

"When we carried out tests in summer 2012 to see whether one of the new molecules might have any effect on arthritis in animals, the results were extremely encouraging."

Substantial international attention

"Our most recent results are especially important now that we have begun negotiating with international pharmaceutical companies towards potential agreements," Berit Johansen says. Three leading pharmaceutical companies are currently courting the Norwegian team.

If the decisive clinical trial proves a success Dr Johansen and her colleagues will enter into discussions on licensing their patent to one of these companies. This will be the company that undertakes the final clinical trials.

Avexxin was recently nominated as one of the world's Top 10 Autoimmune/Anti-Inflammatory companies to watch.

add to favorites email to friend print save as pdf

Related Stories

Small molecules may explain psoriasis

Jul 11, 2007

A research team at the Swedish medical university Karolinska Institutet has shown for the time that microRNA, small RNA molecules, may play an important role in the development of inflammatory skin diseases such as psoriasis ...

Treating psoriasis to prevent heart attacks and strokes

Mar 16, 2012

A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could ...

Recommended for you

Liberia free of Ebola by Christmas, says president

1 hour ago

Liberia's president on Monday urged her countrymen to double their efforts to reach the government's goal of having zero new Ebola cases by Dec. 25, a target some experts have described as highly ambitious.

Madagascar working to contain plague outbreak

1 hour ago

Madagascar said Monday it is trying to contain an outbreak of plague—similar to the Black Death that swept Medieval Europe—that has killed 40 people and is spreading to the capital Antananarivo.

Developing a noninvasive test for endometriosis

1 hour ago

Researchers at UC San Francisco have identified patterns of genetic activity that can be used to diagnose endometriosis and its severity, a finding that may offer millions of women an alternative to surgery through a simple ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.